Glaukos Co. (NYSE:GKOS) Short Interest Up 5.3% in December

Glaukos Co. (NYSE:GKOS – Get Rating) saw a large growth in short interest in December. As of December 30th, there was short interest totalling 4,370,000 shares, a growth of 5.3% from the December 15th total of 4,150,000 shares. Currently, 9.6% of the shares of the company are sold short. Based on an average daily trading volume, of 385,500 shares, the days-to-cover ratio is presently 11.3 days.

Glaukos Price Performance

Shares of NYSE:GKOS opened at $48.17 on Wednesday. The company’s fifty day moving average price is $45.75 and its 200-day moving average price is $50.05. The firm has a market capitalization of $2.30 billion, a price-to-earnings ratio of -25.35 and a beta of 1.23. Glaukos has a one year low of $33.33 and a one year high of $64.49. The company has a debt-to-equity ratio of 0.64, a current ratio of 7.40 and a quick ratio of 6.84.

Glaukos (NYSE:GKOS – Get Rating) last issued its quarterly earnings results on Wednesday, November 2nd. The medical instruments supplier reported ($0.45) EPS for the quarter, topping analysts’ consensus estimates of ($0.53) by $0.08. The firm had revenue of $71.27 million for the quarter, compared to analyst estimates of $67.88 million. Glaukos had a negative net margin of 31.45% and a negative return on equity of 16.16%. On average, equities research analysts anticipate that Glaukos will post -2.23 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research firms recently weighed in on GKOS. JPMorgan Chase & Co. raised shares of Glaukos from an “underweight” rating to a “neutral” rating and decreased their target price for the stock from $48.00 to $42.00 in a report on Monday, December 19th. Citigroup raised shares of Glaukos from a “neutral” rating to a “buy” rating and set a $57.00 target price on the stock in a report on Monday, December 12th. Mizuho began coverage on shares of Glaukos in a report on Thursday, December 22nd. They set a “neutral” rating and a $48.00 target price on the stock. Piper Sandler upped their target price on shares of Glaukos from $55.00 to $60.00 and gave the stock a “neutral” rating in a report on Thursday, November 3rd. Finally, Stephens decreased their target price on shares of Glaukos from $69.00 to $68.00 and set an “overweight” rating on the stock in a report on Wednesday, December 28th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $56.67.

Hedge Funds Weigh In On Glaukos

Several institutional investors and hedge funds have recently made changes to their positions in GKOS. Quadrant Capital Group LLC grew its holdings in shares of Glaukos by 262.4% during the 3rd quarter. Quadrant Capital Group LLC now owns 1,011 shares of the medical instruments supplier’s stock valued at $54,000 after purchasing an additional 732 shares during the last quarter. Captrust Financial Advisors grew its holdings in shares of Glaukos by 17.1% during the 2nd quarter. Captrust Financial Advisors now owns 1,738 shares of the medical instruments supplier’s stock valued at $79,000 after purchasing an additional 254 shares during the last quarter. AlphaCrest Capital Management LLC bought a new position in shares of Glaukos during the 3rd quarter valued at $205,000. Two Sigma Advisers LP bought a new position in shares of Glaukos during the 3rd quarter valued at $207,000. Finally, HighTower Advisors LLC bought a new position in shares of Glaukos during the 1st quarter valued at $208,000. Institutional investors own 92.17% of the company’s stock.

Glaukos Company Profile

(Get Rating)

Glaukos Corp. is an ophthalmic medical technology and pharmaceutical company, which focuses on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases. It engages in development and commercialization of therapies across several end markets within ophthalmology. The company was founded by Olav B.